Journal: BMC Nephrology

Article Title: Intrarenal microRNA signature related to the fibrosis process in chronic kidney disease: identification and functional validation of key miRNAs

doi: 10.1186/s12882-019-1512-x

Figure Lengend Snippet: Overexpression of miRNA mimics inhibits luciferase reporter activity in HK-2 cells. a The schematic luciferase reporter constructs. A mutant construct was made by replacing four nucleotides in the miRNA seed binding site of target gene 3’UTR. Mutated nucleotides were marked in gray and underlined. The luciferase reporter assay of ITGB8 ( b ) and CALM3 ( c ) 3’UTR reporter in HK-2 cells at 48 h after transfection. EV: empty vector; WT: wild-type; Mut: mutant; NC: scrambled negative control transfection.* p < 0.05 versus NC. Data represent mean ± SEM for at least three independent experiments

Article Snippet: The primary antibodies used in this study included ITGB8 (SC-25714, Santa Cruz Biotechnology) and CALM3 (NBP2–15669, Novus Biologicals).

Techniques: Over Expression, Luciferase, Activity Assay, Construct, Mutagenesis, Binding Assay, Reporter Assay, Transfection, Plasmid Preparation, Negative Control

Journal: Frontiers in Immunology

Article Title: Hyaluronic acid−CD44 signaling from decidual stromal cells orchestrates dNK1 differentiation and immune tolerance in early pregnancy

doi: 10.3389/fimmu.2026.1777567

Figure Lengend Snippet: HA-induced activation of the canonical Wnt pathway upregulates FOSL2 to expand the dNK1-like subpopulation. (A) Analysis of transcriptional activity and expression levels of transcription factors in three dNK subsets using scRNA-seq data from normal decidual tissue ( n = 11). (B) Transcriptional activity and expression levels of FOSL2 in decidual tissues from normal pregnancy ( n = 5) and RSA groups ( n = 3). (C) Changes in NK92MI cells of the five transcription factors ( STAT3, MAFB, HES1, FOSL2, ETV5 ) characterized by high transcriptional activity and expression in the dNK1 subset following HMW-HA treatment, as determined by RT−qPCR ( n = 6 per group). (D) FOSL2 expression in NK92MI cells following HMW-HA treatment, assessed by WB ( n = 3 per group). (E) Wnt1 and β-catenin protein expression in NK92MI cells treated with or without HMW-HA in the presence or absence of CD44 blockade ( n = 3 per group). (F) FOSL2 expression in HA−treated NK92MI cells after addition of CD44−blocking antibody or the Wnt pathway inhibitor IWP−2 to the culture system ( n = 3 per group). Data are expressed as mean ± SD; * P < 0.05; ** P < 0.01; ns, not significant. EP, early pregnancy; SA, spontaneous abortion; RSA, recurrent spontaneous abortion.

Article Snippet: The PVDF membranes were incubated overnight at 4 °C with primary antibodies against HAS2 (1:1000; 63kD; Santa Cruz, sc-514737), FOSL2 (1:1000; 45kD; Proteintech, M02615-2), Wnt1 (1:500; 45kD; Boster, PB0408), β-catenin (1:500; 92kD; CST, 8480T) and GAPDH (1:5000; 36kD; Proteintech, HRP-60004).

Techniques: Activation Assay, Activity Assay, Expressing, Quantitative RT-PCR, Blocking Assay

Journal: Scientific Reports

Article Title: α-Synuclein oligomers mediate the aberrant form of spike-induced calcium release from IP 3 receptor

doi: 10.1038/s41598-019-52135-3

Figure Lengend Snippet: α-Synuclein oligomers suppressed CaBP1-induced inactivation of IP R and triggered spike-induced CICR from IP R. A. ( a ) Specimen recordings of I AHP in neurons with αSN or αSNo under the injection of CaBP1 Ab or CaBP1. Scale bars, 500 ms and 20 pA. ( b ) Summary diagram demonstrating average I AHP charge under the infusion of CaBP1 Ab, CaBP1, calmodulin (CaM) Ab, or CaM, each with αSN or αSNo. * p < 0.01, ** p < 0.02 (αSN vs αSNo, t -tests), + p < 0.01, ++ p < 0.02 (CaBP1 Ab vs no drug, αSN, t -tests) ( c ). Specimen recordings of action po t entials during positive current pulse in neurons with αSN or αSNo under the injection of CaBP1 Ab or CaBP1. Scale bars, 100 ms and 10 mV. ( d ) Average spike frequency during current steps under the infusion of CaBP1 Ab, CaBP1, CaM Ab, or CaM, each with αSN or αSNo. For the ‘no drug’ example in ( b , d ), the same data as shown in Fig. are reproduced for clarity. * p < 0.01, ** p < 0.02 (αSNo vs αSN, t -tests), + p < 0.01 (CaBP1 Ab vs no drug, αSN, t -tests).

Article Snippet: The pipette solution also included heparin (low molecular weight; 4 mg/ml; MP Biomedicals), ruthenium red, D-IP 3 , L-IP 3 (100 μM; Alomone Labs), glutathione S-transferase (GST)-CaBP1 (16 nM; Abnova Corp.), calmodulin (3 μM; BioVision Inc.), CaBP1 antibody (10 μg/ml; Novus Biologicals), and calmodulin antibody (10 μg/ml; Novus Biologicals).

Techniques: Injection

Journal: Langmuir

Article Title: Atomic Force Microscopy Study of the Conformational Change in Immobilized Calmodulin

doi: 10.1021/la2016885

Figure Lengend Snippet: Figure 4. Representative AFM topography images of the chemical pattern and protein patterns on the chemical pattern template. The four topography images are rendered on the same 10 nm height scale. (a1) The MUTMS silane pattern self-assembled on the OTSpd pattern. The disk pattern has an SH terminal functional group. (b1) The Ca2+-bound dumbbell-shaped calmodulin (CaM) immobilized on the MUTMS pattern through cys-Hg-S coupling. (c1) The Apo-calmodulin (Apo-CaM) pattern. (d1) The calmodulin pattern treated with CPZ (CPZ-CaM). a2, b2, c2, and d2 are the histograms corresponding to a1, b1, c1, and d1, respectively. The distance between the two peaks in the histogram specifies the height of the disk pattern in the image.

Article Snippet: CaM was also confirmed by western blot analysis utilizing rabbit-raised monoclonal calmodulin primary antibody (EP799Y) and goat-raised antibody against rabbit immunoglobulin G conjugated to alkaline phosphatase (IgG-AP) that were purchased from Novus Biologicals (Littleton, CO).

Techniques: Functional Assay

Journal: Discover Oncology

Article Title: Identification and mechanistic exploration of VEGFA and CALML3 as calcium channel-related prognostic genes in cervical cancer

doi: 10.1007/s12672-026-04683-0

Figure Lengend Snippet: Survival analysis of transcriptome sequencing data and clinical data of cervical cancer samples in the TCGA database. (A) The KM curves of the VEGFA. (B) The KM curves of the CALML3. (C) Nomogram. On the left are the diagnostic factors, each corresponding to a score. The total score is obtained by summing up the scores of all factors (Total Points), and then the survival rate is predicted based on the total score. (D) Nomogram calibration curve. The abscissa represents the predicted survival rate by the nomogram, and the ordinate represents the actual survival rate. (E) DCA curve. The horizontal axis represents the High-Risk Threshold range, and the vertical axis represents the Net Benefit. (F) ROC curve of the diagnostic model

Article Snippet: The sections were allowed to incubate with a CALML3 Polyclonal antibody (1:50 dilution, 117275-1-AP, Proteintech) and VEGFA polyclonal antibody (1:50 dilution, 19003-1-AP, Proteintech) at 4 °C overnight.

Techniques: Sequencing, Diagnostic Assay

Journal: Discover Oncology

Article Title: Identification and mechanistic exploration of VEGFA and CALML3 as calcium channel-related prognostic genes in cervical cancer

doi: 10.1007/s12672-026-04683-0

Figure Lengend Snippet: GSEA enrichment trend plot. (A) GSEA enrichment of VEGFA. Present only the five most enriched pathways, ordered by their enrichment score (ES), in a figure comprising three sections. The upper section illustrates the computation of the ES value. For each gene from left to right, an ES value is calculated and connected to form a line. On the leftmost side, a particularly prominent peak represents the ES value for the gene set phenotype. The middle part of the figure features each line representing a gene in the gene set and its ranking position in the gene list. The bottom part displays the matrix of gene-phenotype associations. (B) GSEA enrichment of CALML3

Article Snippet: The sections were allowed to incubate with a CALML3 Polyclonal antibody (1:50 dilution, 117275-1-AP, Proteintech) and VEGFA polyclonal antibody (1:50 dilution, 19003-1-AP, Proteintech) at 4 °C overnight.

Techniques: